Anja Schmitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anja Schmitt has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Hailfinger
Department of Medicine A, Münster University Hospital, Münster, GERMANY
4 shared publications Caroline Schönfeld
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany
2 shared publications- Claudia Lengerke
University Hospital Tübingen
2 shared publications - Daniela Kramer
Interfaculty Institute for Biochemistry, Eberhard Karls University of Tübingen, Tübingen, Germany
2 shared publications Georg Lenz
Department of Medicine A – Hematology, Oncology and Pneumology, University Hospital Münster, Muenster, Germany
2 shared publicationsKlaus Schulze-Osthoff
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1779, 467023
In-depth phospholipid profiling of lymphoma cells by HPLC coupled with trapped ion mobility spectrometry and high-resolution tandem mass spectrometry
- 21 April 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1779, 467023
Open AccessIn-depth phospholipid profiling of lymphoma cells by HPLC coupled with trapped ion mobility spectrometry and high-resolution tandem mass spectrometry
- Open Access
- 27 March 2024
- Published by ScienceOpen
Metabolic dysfunction-associated steatotic liver disease can be alleviated by activating NO/cGMP signaling
Metabolic dysfunction-associated steatotic liver disease encompasses a spectrum of chronic liver diseases ranging from steatosis to metabolic dysfunction-associated steatohepatitis (MASH). Hepatic stellate cells (HSCs), the pericytes of the liver, have been associated with the pathogenesis of MASH. In diseased livers, HSCs transdifferentiate into αSMA+ myofibroblasts. In this activated stage, they produce excess collagen as well as proinflammatory and profibrogenic cytokines. HSCs are known to express proteins of the NO/cGMP pathway. We hypothesized that modulation of this pathway may alter HSC transdifferentiation and thereby the progression of MASH. As a model for MASH, we used ApoE-deficient mice fed a Western diet. In comparison to wild-type mice receiving a normal diet, these animals showed characteristics of MASH, such as steatosis, fibrosis, and inflammation. Both quiescent HSCs and activated αSMA+ myofibroblasts expressed NO-sensitive guanylyl cyclase (NO-GC) and cGMP-dependent protein kinase type I (cGKI), indicating the existence of a functional NO/cGMP pathway in healthy as well as MASH livers. This was further supported by the real-time detection of NO-induced cGMP signals in HSCs isolated from mice expressing a FRET-based cGMP sensor. Moreover, we show that pharmacological treatment with a NO-GC activator elevates cGMP in HSCs and attenuates the pathological phenotype of MASH invivo. In drug-treated mice, we found a reduced amount of fat bubbles and fibrosis, decreased liver enzyme levels, and decreased expression of markers for activated myofibroblasts. In conclusion, we report the NO/cGMP/cGKI signaling pathway as a marker of HSCs and NO-GC activators as potential drugs for the treatment of MASH.
- 27 March 2024
- Published by ScienceOpen
Open AccessMetabolic dysfunction-associated steatotic liver disease can be alleviated by activating NO/cGMP signaling
Metabolic dysfunction-associated steatotic liver disease encompasses a spectrum of chronic liver diseases ranging from steatosis to metabolic dysfunction-associated steatohepatitis (MASH). Hepatic stellate cells (HSCs), the pericytes of the liver, have been associated with the pathogenesis of MASH. In diseased livers, HSCs transdifferentiate into αSMA+ myofibroblasts. In this activated stage, they produce excess collagen as well as proinflammatory and profibrogenic cytokines. HSCs are known to express proteins of the NO/cGMP pathway. We hypothesized that modulation of this pathway may alter HSC transdifferentiation and thereby the progression of MASH. As a model for MASH, we used ApoE-deficient mice fed a Western diet. In comparison to wild-type mice receiving a normal diet, these animals showed characteristics of MASH, such as steatosis, fibrosis, and inflammation. Both quiescent HSCs and activated αSMA+ myofibroblasts expressed NO-sensitive guanylyl cyclase (NO-GC) and cGMP-dependent protein kinase type I (cGKI), indicating the existence of a functional NO/cGMP pathway in healthy as well as MASH livers. This was further supported by the real-time detection of NO-induced cGMP signals in HSCs isolated from mice expressing a FRET-based cGMP sensor. Moreover, we show that pharmacological treatment with a NO-GC activator elevates cGMP in HSCs and attenuates the pathological phenotype of MASH invivo. In drug-treated mice, we found a reduced amount of fat bubbles and fibrosis, decreased liver enzyme levels, and decreased expression of markers for activated myofibroblasts. In conclusion, we report the NO/cGMP/cGKI signaling pathway as a marker of HSCs and NO-GC activators as potential drugs for the treatment of MASH.
- 19 April 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (10) , 871-884
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL
Despite the development of novel targeted drugs, the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) still poses a substantial therapeutic challenge. DLBCL can be classified into at least 2 major subtypes (germinal center B cell [GCB]-like and activated B cell [ABC]-like DLBCL), each characterized by specific gene expression profiles and mutation patterns. Here we demonstrate a broad antitumor effect of dimethyl fumarate (DMF) on both DLBCL subtypes, which is mediated by the induction of ferroptosis, a form of cell death driven by the peroxidation of phospholipids. As a result of the high expression of arachidonate 5-lipoxygenase in concert with low glutathione and glutathione peroxidase 4 levels, DMF induces lipid peroxidation and thus ferroptosis, particularly in GCB DLBCL. In ABC DLBCL cells, which are addicted to NF-κB and STAT3 survival signaling, DMF treatment efficiently inhibits the activity of the IKK complex and Janus kinases. Interestingly, the BCL-2–specific BH3 mimetic ABT-199 and an inhibitor of ferroptosis suppressor protein 1 synergize with DMF in inducing cell death in DLBCL. Collectively, our findings identify the clinically approved drug DMF as a promising novel therapeutic option in the treatment of both GCB and ABC DLBCLs.
- 19 April 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (10) , 871-884
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL
Despite the development of novel targeted drugs, the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) still poses a substantial therapeutic challenge. DLBCL can be classified into at least 2 major subtypes (germinal center B cell [GCB]-like and activated B cell [ABC]-like DLBCL), each characterized by specific gene expression profiles and mutation patterns. Here we demonstrate a broad antitumor effect of dimethyl fumarate (DMF) on both DLBCL subtypes, which is mediated by the induction of ferroptosis, a form of cell death driven by the peroxidation of phospholipids. As a result of the high expression of arachidonate 5-lipoxygenase in concert with low glutathione and glutathione peroxidase 4 levels, DMF induces lipid peroxidation and thus ferroptosis, particularly in GCB DLBCL. In ABC DLBCL cells, which are addicted to NF-κB and STAT3 survival signaling, DMF treatment efficiently inhibits the activity of the IKK complex and Janus kinases. Interestingly, the BCL-2–specific BH3 mimetic ABT-199 and an inhibitor of ferroptosis suppressor protein 1 synergize with DMF in inducing cell death in DLBCL. Collectively, our findings identify the clinically approved drug DMF as a promising novel therapeutic option in the treatment of both GCB and ABC DLBCLs.
- 1 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (9) , 1805-1814.e6
Threonine Phosphorylation of IκBζ Mediates Inhibition of Selective Proinflammatory Target Genes
- 1 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (9) , 1805-1814.e6
Threonine Phosphorylation of IκBζ Mediates Inhibition of Selective Proinflammatory Target Genes
- 9 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (2) , 121-132
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.
- 9 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (2) , 121-132
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.
- 3 February 2012
- Published by Wiley in Histopathology
- Vol. 60 (5) , 774-784
Extranodal diffuse large B cell lymphoma of cutaneous follicle centre lymphoma type: a study of 24 patients with non‐cutaneous primary limited stage extranodal diffuse large B cell lymphoma in support of a new concept
Aigner F, Korol D, Schmitt A M & Kurrer M O (2012) Histopathology 60, 774–784 Extranodal diffuse large B cell lymphoma of cutaneous follicle centre lymphoma type: a study of 24 patients with non-cutaneous primary limited stage extranodal diffuse large B cell lymphoma in support of a new concept Aims: Follicle centre cell lymphoma of small cell type showing either a follicular or diffuse growth pattern similar to cutaneous follicle centre lymphoma (cFCL) has been recognized in extranodal non-cutaneous sites. Our aim was (i) to investigate whether diffuse large B cell lymphoma (DLBCL) of cFCL type could be identified in extranodal non-cutaneous sites and (ii) whether clinical characteristics similar to primary cFCL could be recognized. Methods and results: Of 24 extranodal non-cutaneous DLBCLs, nine (38%) had large centrocytoid morphology and 15 (62%) were either ‘centrocytoid and centroblastic’ or ‘centroblastic and immunoblastic’. Six centrocytoid cases were Irf-4 negative, Bcl-6 positive and at most weakly CD10- or Bcl-2-positive by immunohistochemistry, consistent with DLBCL of cFCL type. All patients with cFCL type were stage IE and were significantly younger than other patients. Recurrences occurred in two patients and were exclusively extranodal. Conclusion: Our results suggest that DLBCL of cFCL type can be identified in extranodal non-cutaneous sites and shows clinical characteristics similar to genuine cFCL. We propose to expand the concept of cFCL to encompass large cell lymphomas in extranodal sites.
- 3 February 2012
- Published by Wiley in Histopathology
- Vol. 60 (5) , 774-784
Extranodal diffuse large B cell lymphoma of cutaneous follicle centre lymphoma type: a study of 24 patients with non‐cutaneous primary limited stage extranodal diffuse large B cell lymphoma in support of a new concept
Aigner F, Korol D, Schmitt A M & Kurrer M O (2012) Histopathology 60, 774–784 Extranodal diffuse large B cell lymphoma of cutaneous follicle centre lymphoma type: a study of 24 patients with non-cutaneous primary limited stage extranodal diffuse large B cell lymphoma in support of a new concept Aims: Follicle centre cell lymphoma of small cell type showing either a follicular or diffuse growth pattern similar to cutaneous follicle centre lymphoma (cFCL) has been recognized in extranodal non-cutaneous sites. Our aim was (i) to investigate whether diffuse large B cell lymphoma (DLBCL) of cFCL type could be identified in extranodal non-cutaneous sites and (ii) whether clinical characteristics similar to primary cFCL could be recognized. Methods and results: Of 24 extranodal non-cutaneous DLBCLs, nine (38%) had large centrocytoid morphology and 15 (62%) were either ‘centrocytoid and centroblastic’ or ‘centroblastic and immunoblastic’. Six centrocytoid cases were Irf-4 negative, Bcl-6 positive and at most weakly CD10- or Bcl-2-positive by immunohistochemistry, consistent with DLBCL of cFCL type. All patients with cFCL type were stage IE and were significantly younger than other patients. Recurrences occurred in two patients and were exclusively extranodal. Conclusion: Our results suggest that DLBCL of cFCL type can be identified in extranodal non-cutaneous sites and shows clinical characteristics similar to genuine cFCL. We propose to expand the concept of cFCL to encompass large cell lymphomas in extranodal sites.
- 1 January 2011
- Published by S. Karger AG in Onkologie
- Vol. 34 (3) , 139-146
Clinical Aspects, Diagnostic Challenges and Management of Patients with Neuroendocrine Tumors (NETs)
Neuroendocrine tumor (NET) entities are rare malignancies. Higher awareness and improved diagnostic methods have led to an increasing incidence of these diseases, and most oncologists deal with such patients in their daily practice. The symposium on NETs that was held in Merano (Italy) in October 2009 was organized by the German-speaking European School of Oncology (dESO) and gathered specialists from different disciplines of transalpine countries to bring together experiences and observations regarding these tumors. The goal of the meeting and of this review was to illustrate both well- and poorly differentiated NETs and to encourage interdisciplinary approaches.
- 1 January 2011
- Published by S. Karger AG in Onkologie
- Vol. 34 (3) , 139-146
Clinical Aspects, Diagnostic Challenges and Management of Patients with Neuroendocrine Tumors (NETs)
Neuroendocrine tumor (NET) entities are rare malignancies. Higher awareness and improved diagnostic methods have led to an increasing incidence of these diseases, and most oncologists deal with such patients in their daily practice. The symposium on NETs that was held in Merano (Italy) in October 2009 was organized by the German-speaking European School of Oncology (dESO) and gathered specialists from different disciplines of transalpine countries to bring together experiences and observations regarding these tumors. The goal of the meeting and of this review was to illustrate both well- and poorly differentiated NETs and to encourage interdisciplinary approaches.